480 Pleasant Street
United States - Map
pSivida Corp. develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also develops Medidur, an injectable, sustained-release micro-insert designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye, which is in pivotal Phase III clinical trials. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.
|Dr. Paul Ashton B.Sc., Ph.D.,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Leonard S. Ross ,
Principal Financial & Accounting Officer and VP of Fin.
|Ms. Lori H. Freedman Esq., B.A., J.D.,
VP of Corp. Affairs, Gen. Counsel and Company Sec.
|Mr. Marty Nazzaro ,
VP of Operations
|Dr. Anna Kluczewska B.D.Sc.,
Chief Exec. Officer of AION Diagnostics Limited, Pres of AION Diagnostics Limited and Director of AION Diagnostics Limited
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|